Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-203a-3p inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intrathecal, Intravitreal, Inhalation, Intranasal, Implant
01
Overview
miR-203a-3p inhibitor is a synthetic oligonucleotide designed to bind and sequester the microRNA miR-203a-3p, thereby preventing it from interacting with its target messenger RNAs. In the context of esophageal cancer (EC) research, miR-203a-3p has been identified as a potential tumor suppressor that directly targets the 3'-UTR of GATA Binding Protein 6 (GATA6). Experimental inhibition of miR-203a-3p in esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) cell lines leads to an increase in GATA6 expression and a corresponding increase in cell proliferation rates. This inhibitor is primarily utilized as a research tool to elucidate the functional role of miR-203a-3p in oncogenesis and to validate its regulatory relationship with downstream effectors like GATA6.
- Other names
- anti-miR-203a-3panti-miR203a-3panti-miR 203a-3pantagomir-203a-3pantagomir203a-3pantagomir 203a-3pmiR-203a-3p antagomirmiR203a-3p antagomirmiR 203a-3p antagomir
Beyond the preview
Go deeper on miR-203a-3p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-203a-3p inhibitor.